ライフサイエンスコーパス: teriparatide

1 for combination to denosumab vs denosumab to teriparatide).

2 rom bisphosphonates to denosumab, as well as teriparatide.

3 eosarcoma has been reported in a woman using teriparatide.

4 hosphonate therapy may blunt the efficacy of teriparatide.

5 < 0.001) in patients treated with 20 mug/day teriparatide.

6 ratory end point) for abaloparatide than for teriparatide.

7 gains in hip BMD that were not observed with teriparatide.

8 atment attenuates the bone-forming effect of teriparatide.

9 eases of 4.1% with alendronate and 7.1% with teriparatide.

10 e combination group (4.2% [3.0]) than in the teriparatide (0.8% [4.1], p=0.0007) and denosumab (2.1%

11 did total-hip BMD (combination, 4.9% [2.9]; teriparatide, 0.7% [2.7], p<0.0001; denosumab 2.5% [2.6]

12 ants were randomly assigned (1:1) to receive teriparatide 20 mug (standard dose) or 40 mug (high dose

13 re randomly assigned to receive 24 months of teriparatide (20 mg daily), denosumab (60 mg every 6 mon

14 l alendronate (70 mg weekly) or subcutaneous teriparatide (20 mug daily).

15 ozumab (210 mg once monthly) or subcutaneous teriparatide (20 mug once daily).

16 tal surgery and received daily injections of teriparatide (20 mug) or placebo, along with oral calciu

17 allocated to either 8 weeks of subcutaneous teriparatide (20 ug/day) or placebo injections, in addit

18 Combined treatment with teriparatide 40 mug and denosumab increases spine and hi

19 mbination group (9.1%, [SD 3.9]) than in the teriparatide (6.2% [4.6], p=0.0139) or denosumab (5.5% [

20 Intermittent administration of teriparatide, a drug composed of the first 34 amino acid

21 Teriparatide, a PTH1R agonist that inhibits murine vascu

22 Teriparatide, a recombinant form of parathyroid hormone

23 Anabolic medications (teriparatide, abaloparatide, and romosozumab) should be

24 In the Denosumab and Teriparatide Administration (DATA) study, we showed that

25 Favorable outcomes have emerged with teriparatide administration in patients with osteonecros

26 assessed outcomes of periodontal surgery and teriparatide administration in vitamin-D-sufficient and

27 a preplanned extension of the denosumab and teriparatide administration study (DATA), in which 94 po

28 The increase in early precursors after teriparatide administration was associated with robust s

29 Teriparatide, an analogue of the first 34 amino acids of

30 Teriparatide, an osteoanabolic agent that improves bone

31 randomly assigned to receive, in addition to teriparatide and 1000 IU cholecalciferol, 1800 mg calciu

32 Overall, both teriparatide and abaloparatide have demonstrated convinc

33 nt with parathyroid hormone analogs (such as teriparatide and abaloparatide) and sclerostin inhibitor

34 Combined teriparatide and denosumab increased BMD more than eithe

35 The DATA study showed that combined teriparatide and denosumab increased bone mineral densit

36 Effects of teriparatide and denosumab on BMD and fractures are uncl

37 We compared combined teriparatide and denosumab with both agents alone.

38 Discontinuing teriparatide and denosumab, however, results in rapidly

39 thyroid hormone, used clinically as the drug teriparatide) and glucagon-like peptide-1 (7-36) (GLP-1(

40 Teriparatide, as compared with placebo, was associated w

41 Current treatments, such as teriparatide, boost bone formation but also elevate reso

42 s increased in both groups, as expected with teriparatide, but the increases in the 2 calcium groups

43 assigned in a 1:1:1 ratio to receive 20 mug teriparatide daily, 60 mg denosumab every 6 months, or b

44 se originally assigned to denosumab received teriparatide (denosumab to teriparatide group), and thos

45 % [95% CI 5.3-7.9]) than in the denosumab to teriparatide group (2.8% [1.3-4.2], p=0.0002), but had t

46 p (9.1% [6.1-12.0]) than in the denosumab to teriparatide group (4.9% [2.2-7.5]; p=0.0447 for teripar

47 ctures occurred in 25 (4.0%) patients in the teriparatide group and 38 (6.1%) in the risedronate grou

48 occurred in 28 (5.4%) of 680 patients in the teriparatide group and 64 (12.0%) of 680 patients in the

49 occurred in 30 (4.8%) of 680 patients in the teriparatide group compared with 61 (9.8%) of 680 in the

50 Significantly more patients in the teriparatide group had at least one elevated measure of

51 One participant in the denosumab to teriparatide group had nephrolithiasis, classified as be

52 Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1% +/- 1.

53 ewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% v

54 t the lumbar spine had increased more in the teriparatide group than in the alendronate group (7.2+/-

55 sumab group, and p=0.41 for the denosumab to teriparatide group vs the combination to denosumab group

56 nosumab group; p=0.0099 for the denosumab to teriparatide group vs the combination to denosumab group

57 ents in the romosozumab group and 209 in the teriparatide group were included in the primary efficacy

58 mosozumab group compared with 12 (6%) in the teriparatide group with adverse events leading to invest

59 enosumab received teriparatide (denosumab to teriparatide group), and those originally assigned to bo

60 romosozumab group vs 22 [10%] of 214 in the teriparatide group), hypercalcaemia (two [<1%] vs 22 [10

61 enosumab group, p<0.0001 vs the denosumab to teriparatide group).

62 .0% (10.9-17.2) in 27 women the denosumab to teriparatide group, and 16.0% (14.0-18.0) in 23 women in

63 d by -1.8% (-5.0 to 1.3) in the denosumab to teriparatide group, and increased by 2.8% (1.2-4.4) in t

64 atide to denosumab group vs the denosumab to teriparatide group, p=0.30 for the teriparatide to denos

65 y at the total hip had increased more in the teriparatide group.

66 h 3 of 444 patients (0.7%) in the 20 mug/day teriparatide group.

67 ozumab group and -0.6% (-1.0 to -0.2) in the teriparatide group; difference 3.2% (95% CI 2.7 to 3.8;

68 Although teriparatide has been evaluated for the treatment of ost

69 patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for

70 Teriparatide improves the rate of resolution of MRONJ le

71 nt in opposing the anti-apoptotic effects of teriparatide in these cells, thereby maintaining normal

72 arathyroid hormone (PTH) (1-34) (also called teriparatide) in LDLR -/- mice fed diabetogenic diets fo

73 Teriparatide increases osteoblast numbers by suppressing

74 Thus, teriparatide increases the numbers of early cells of the

75 We show that teriparatide increases the numbers of osteoblast precurs

76 th less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as incre

77 bone resorption while allowing for continued teriparatide-induced bone formation, resulting in larger

78 udy, we showed that denosumab fully inhibits teriparatide-induced bone resorption while allowing for

79 Teriparatide-induced elevation of P1NP levels was less p

80 NSAIDs and teriparatide may be the preferred treatment options for

81 Teriparatide may offer therapeutic potential for localiz

82 that PTH receptor expression is required for teriparatide-mediated increases in early osteoblast prec

83 randomly assigned to romosozumab (n=218) or teriparatide (n=218).

84 gned to 20 mug teriparatide (n=39) or 40 mug teriparatide (n=37), of whom 69 completed at least one p

85 articipants were randomly assigned to 20 mug teriparatide (n=39) or 40 mug teriparatide (n=37), of wh

86 ) patients on romosozumab and in 23 (11%) on teriparatide; none were judged treatment related.

87 5), a sclerostin monoclonal antibody, versus teriparatide on bone mineral density (BMD) in women with

88 ut do not directly demonstrate, a benefit of teriparatide on HRQOL.

89 were randomly assigned to receive 20 mug of teriparatide once daily plus oral weekly placebo or 35 m

90 total of 214 patients received 20 microg of teriparatide once daily, and 214 received 10 mg of alend

91 Randomized controlled trials with teriparatide or abaloparatide have also provided evidenc

92 h or imminent risk of fracture, therapy with teriparatide or abaloparatide should be considered; howe

93 vitamin D supplements, and self-administered teriparatide or placebo for 6 wks to correspond with oss

94 observations (eg, oestrogen, calcitonin, and teriparatide) or opportunistic repurposing of existing c

95 0 mug recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind

96 or teriparatide to denosumab vs denosumab to teriparatide, p=0.0336 for combination to denosumab vs d

97 ficant impact on CAL and PPD improvements in teriparatide patients at 1 yr, but infrabony defect reso

98 Continued therapy with teriparatide prevented the appearance of adipocytes.

99 f osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab) compared with p

100 In DATA-Switch, women originally assigned to teriparatide received denosumab (teriparatide to denosum

101 ores, and if so, to determine the effects of teriparatide (recombinant human parathyroid hormone 1-34

102 Teriparatide, recombinant human PTH(1-34), is likely to

103 vidence that bisphosphonates, denosumab, and teriparatide reduce fractures compared with placebo, wit

104 Teriparatide reduces the risk of nonvertebral and verteb

105 ncrease, whereas switching from denosumab to teriparatide results in progressive or transient bone lo

106 No direct evidence for teriparatide's actions on early cells of the osteoblast

107 density increased more in patients receiving teriparatide than in those receiving alendronate.

108 is significantly lower in patients receiving teriparatide than in those receiving risedronate.

109 l improvement was greater in patients taking teriparatide than in those taking placebo, with a reduct

110 studies have shown favorable responses with teriparatide (the biologically active fragment of PTH) a

111 bolic responses in excess of those seen with teriparatide, the only currently available anabolic skel

112 en N-telopeptide (NTx) levels increased with teriparatide therapy (135% +/- 14% and 64% +/- 10% chang

113 Vertebral vBMD and strength improved with teriparatide therapy (18% +/- 6% and 15% +/- 3% change,

114 eous defects was significantly greater after teriparatide therapy than after placebo beginning at 6 m

115 Unexpectedly, following withdrawal of teriparatide therapy, bone marrow adipocytes increased d

116 us bone mineral density was unchanged in the teriparatide to denosumab group (0.0% [95% CI -1.3 to 1.

117 p bone mineral density increased more in the teriparatide to denosumab group (6.6% [95% CI 5.3-7.9])

118 k bone mineral density increased more in the teriparatide to denosumab group (8.3% [95% CI 6.1-10.5])

119 n the combination to denosumab group and the teriparatide to denosumab group did not differ significa

120 osumab to teriparatide group, p=0.30 for the teriparatide to denosumab group vs the combination to de

121 ination to denosumab group (p=0.0075 for the teriparatide to denosumab group vs the combination to de

122 or between-group comparisons, p=0.13 for the teriparatide to denosumab group vs the denosumab to teri

123 assigned to teriparatide received denosumab (teriparatide to denosumab group), those originally assig

124 18.3% (95% CI 14.9-21.8) in 27 women in the teriparatide to denosumab group, 14.0% (10.9-17.2) in 27

125 umab group (8.6% [7.1-10.0]; p=0.0446 vs the teriparatide to denosumab group, p<0.0001 vs the denosum

126 paratide group (4.9% [2.2-7.5]; p=0.0447 for teriparatide to denosumab vs denosumab to teriparatide,

127 menopausal osteoporotic women switching from teriparatide to denosumab, bone mineral density continue

128 t infrabony defect resolution was greater in teriparatide-treated vitamin-D-sufficient vs. -deficient

129 s who are clinically stable, and considering teriparatide treatment in individuals who experience an

130 Teriparatide treatment significantly reduced the risk of

131 ad scans at baseline and 6 mo after starting teriparatide treatment were used to compare response to

132 were 14.4%-14.8%, and treatment response to teriparatide was 23.2%-23.8%.

133 Teriparatide was also associated with reduced bony defec

134 Teriparatide was associated with a greater rate of resol

135 nsity, and strength, at levels comparable to teriparatide, while significantly reducing bone resorpti

136 clinical trial in 211 patients treated with teriparatide who consumed <1000 mg phosphorus/d.

137 double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with

138 We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe os

139 .13; 95% CI, 0.05 to 2.21) administration of teriparatide, with no treatment being superior to NSAIDs

140 r administration of denosumab with high dose teriparatide would stimulate larger increases in bone ma